Rein Therapeutics, Inc. Common Stock RNTX Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $0— | $0— | $0— | $0— | $0— | ||
| $11.05M-20.2% | $11.03M-22.6% | $12.35M-4.3% | $14.39M+56.4% | $13.84M+145% | ||
| $10.51M-17.1% | $10.9M-21.4% | $11.42M-31.7% | $9.96M-39.0% | $12.68M-1.9% | ||
| $50.25M-20.9% | $50.63M-22.2% | $60.77M+105% | $61.35M+140% | $63.52M+244% | ||
| -$50.25M+20.9% | -$50.63M+22.2% | -$60.77M-105% | -$61.35M-140% | -$63.52M-244% | ||
| —— | —— | $340K-17.7% | $653K+89.3% | $701K+54.7% | ||
| —— | -$712K+53.9% | -$920K+20.6% | -$1.13M-46.1% | -$1.34M-246% | ||
| -$50.21M+18.1% | -$49.87M+20.7% | -$58.89M-101% | -$59.15M-135% | -$61.27M-239% | ||
| -$1.90+40.1% | -$1.96+48.1% | -$2.94+6.7% | -$3.00+8.5% | -$3.17+1.6% | ||
| -$50.25M+20.9% | -$50.63M+22.2% | -$60.77M-105% | -$61.35M-140% | -$63.52M-244% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Rein Therapeutics, Inc. Common Stock profitable?
- Rein Therapeutics, Inc. Common Stock is not currently profitable: it reported a net loss of $50.2M over the trailing twelve months.
- What is Rein Therapeutics, Inc. Common Stock's earnings per share?
- Rein Therapeutics, Inc. Common Stock's diluted EPS over the trailing twelve months is $-1.90.
- Where does Rein Therapeutics, Inc. Common Stock's income statement data come from?
- Every line is extracted from Rein Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.